Actively Recruiting
Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study
Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2023-05-10
48
Participants Needed
3
Research Sites
410 weeks
Total Duration
On this page
Sponsors
L
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
A
Academic Medical Organization of Southwestern Ontario
Collaborating Sponsor
AI-Summary
What this Trial Is About
External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 3 or 4 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. This study investigates the role of shortened external radiotherapy regimen (hypofractionated radiotherapy) by randomizing patients to this experimental regimen versus the standard of care.The purpose of this study is to access the feasibility of patient accrual to this trial in the Canadian setting and to provide an initial evaluation of cancer response and treatment tolerability.
CONDITIONS
Official Title
Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- FIGO stage IA or IB1 cervical cancer if not surgical candidates but suitable for chemoradiotherapy
- FIGO stage IB2, IB3, IIA, or IIB cervical cancers
- FIGO stage IIIC1 cervical cancers with largest node less than 3 cm, fewer than 3 pathological nodes, no common iliac chain nodes, and cervical confined or with parametrial invasion
- Histologically confirmed invasive uterine cervical carcinoma of squamous cell, adenocarcinoma, or adenosquamous cell subtypes
- Candidate for definitive chemoradiotherapy with weekly cisplatin
- Candidate for brachytherapy
You will not qualify if you...
- FIGO stage IIIA, IIIB, IIIC2, IVA, or IVB
- FIGO stage IIIC1 with node greater than 3 cm, common iliac node involvement, or more than 2 pathological nodes
- Previous pelvic or abdominal radiotherapy
- Need for paraaortic nodal irradiation
- Inflammatory bowel disease
- Connective tissue disorders such as scleroderma or systemic lupus erythematous
- Histologies including neuroendocrine, glassy cell, small cell, adenoid cystic, adenoid basal, clear cell, serous, endometrioid, verrucous carcinoma, melanoma, or sarcoma
- Unable to undergo MR scan
- ECOG performance status greater than 3
- Not a candidate for cisplatin chemotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
BC Cancer - Kelowna
Kelowna, British Columbia, Canada, V1Y 5L3
Actively Recruiting
2
London Health Sciences Centre - London Regional Cancer Program
London, Ontario, Canada, N6A 5W9
Actively Recruiting
3
Odette Cancer Centre - Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
L
Lucas C Mendez, MD
CONTACT
D
David D'Souza, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here